Psilocybin Treatments

Debate between Robert Jenrick and Charlotte Nichols

Thursday 18th May 2023 Commons Chamber

[Robert Jenrick]

I am afraid I do not know the precise departmental visit that my right hon. Friend the Member for Croydon South is on. But knowing him, if he was here, he would certainly wish to be part of this debate and to continue the conversation that he has had with hon. Friend the Member for Reigate. It is only because of other departmental business that he was not able to join us today.

I want to begin by recognising, as others have done, the personal interest that the hon. Member for Warrington North has in this topic. I concur with your comments, Madam Deputy Speaker, that the hon. Member spoke with great conviction and very deeply. I have heard her speak on other subjects that we have a shared interest in, such as the fight against antisemitism, with the same eloquence and bravery that she showed today.

It may be helpful at the outset to remind the House that medicines policy, including the availability of medicines for prescribing, is led by the Department of Health and Social Care. Medicines are licensed and regulated by the Medicines and Healthcare products Regulatory Agency. However, the Home Office is responsible for controlled drugs legislation. Our controlled drugs licensing regime supports research and clinical trials in the UK. The two Departments work together on issues connected to controlled drugs in healthcare. I will endeavour to set out the Government’s position this afternoon.

Controlled drugs legislation seeks to prevent criminality while permitting access for legitimate use, including for medicines development. The Misuse of Drugs Regulations 2001 enable the use of controlled drugs in healthcare. The Home Office’s controlled drugs licensing regime enables the possession, supply, production, import and export of controlled drugs to support industry, pharmaceutical research and healthcare. These controls are subject to review in light of any emerging evidence and in consultation with the Advisory Council on the Misuse of Drugs, which has been referenced many times this afternoon.

There is an established process for medicines, including those that contain controlled drugs, to be developed, evaluated in clinical trials and licensed, based on an assessment of their quality, safety and efficacy by the MHRA. The MHRA supports the safe and scientifically sound conduct of clinical trials in this area, and provides regulatory and scientific advice to companies at all stages of developing medicines. Should a company submit an application for a marketing authorisation, otherwise known as product licence, it will ultimately be a decision for the MHRA whether to license a product based on a psychedelic drug as a therapy.

[Charlotte Nichols]

The Minister refers to marketing authorisation. In this case, psilocybin, as we have discussed, is something that grows in mushrooms across the UK. Is the Minister suggesting that people would be able to access psilocybin only if it were in another substance?

[Robert Jenrick]

I am by no means an expert in this field, but I think I am suggesting that were this to be a drug that is licensed, it would need to go through the MHRA process in the usual way.

I would like to come to a point made by the hon. Lady earlier around the costs involved in a first-time application for a controlled drug licence of the kind we have been discussing. She quoted a substantial figure, which would be concerning as it would be prohibitively costly for smaller manufacturers or researchers. The figures that I have been quoted are that first-time application for a licence costs £3,700 and a standard renewal costs £326. I will write to the hon. Lady with those figures and if she contests them in any way, then I or the Minister for Crime, Policing and Fire, my right hon. Friend the Member for Croydon South (Chris Philp) will be happy to respond.

--- Later in debate ---

[Robert Jenrick]

My hon. Friend has made his point very powerfully. Of course the Government’s ambition is to ensure that NICE, the MHRA and all our regulators work in the most research-friendly manner, and that applies to mental health treatments as much as to anything else.

If a manufacturer is successful in being granted a marketing authorisation by the MHRA for a medicine containing psilocybin, the Home Office is committed to swift action to remove psilocybin from schedule 1 and make it available for prescribing, subject to advice from the Advisory Council on the Misuse of Drugs on the appropriate scheduling and safeguards for the medicine. The same scrutiny should be applied to all potential medicines to ensure patient safety. While it is legally possible to enable prescribing in advance of marketing authorisation, the Government currently have no plans to move to that position.

[Charlotte Nichols]

The Minister keeps referring to medicines containing psilocybin. He does not seem to understand that psilocybin is the medicine, in and of itself. It does not need to be added to something else to make it work. This is why we are running into the issue. The Government keep telling us about a licensing regime in which there is a requirement to add something to the compound in order to make it some sort of novel substance, rather than looking at the substance that already exists and, as we have said, has been used for thousands of years with demonstrated safety and efficacy. Will the Minister talk about psilocybin, rather than medicines containing psilocybin?

[Robert Jenrick]

I understand the hon. Lady’s point. As I have said, the Government are funding research into psilocybin and its effect on patients with certain conditions. What we are discussing today is the Home Office’s role in ensuring that that research, as it emerges, can be considered as part of our drugs legalisation framework.

The Government have commissioned the ACMD to consider how better to enable research with respect to all schedule 1 drugs, and that includes the potential to extend schedule 2 status for research purposes to all schedule 1 drugs including psilocybin. This, I believe, is the point that my right hon. Friend the Minister for Crime, Policing and Fire made in the Adjournment debate, and he has written to the ACMD asking it to consider, in particular, the potential options available to extend schedule 2 status for research purposes to all schedule 1 drugs. He highlighted psilocybin specifically in his letter. If the hon. Member for Warrington North, my hon. Friend the Member for Reigate or, indeed, other interested Members have not seen it, I shall be happy to ensure that they receive a copy and can see the instructions that my right hon. Friend has given to the ACMD. My hon. Friend the Member for Reigate asked earlier about the likely timetable for any advice from the ACMD. I have been told that, while the ACMD is independent of Government, it is understood that its consideration is well advanced, and we should expect its advice in the near future.

The approach that we have taken in this regard should deliver much of what my hon. Friend and others are requesting. I should make a distinction: prescribing will remain unavailable outside a clinical trial. It is not for the Home Office to determine medicines policy, and I am sure that my hon. Friend and others will accept the general principle that medicines should be assessed on the basis of their safety, quality and efficacy before being made available to patients.

The two Departments continue to support the ACMD’s review. The chief scientific adviser to the Home Office recently convened a discussion with her counterpart in the Department of Health and Social Care and the Government’s chief medical officer on this precise subject. I understand that they had a very positive discussion and I know that they will be advocating for the best outcome for researchers and, of course, patients. When the ACMD provides its advice, the Government will consider it carefully before deciding how to proceed.

I thank Members for their contributions to the debate. I can assure my hon. Friend the Member for Reigate and others that the Government have heard what they have to say. I will ensure that my right hon. Friend the Minister for Crime, Policing and Fire is fully apprised of what was said in the debate, so that he and others can continue their conversation on this issue.

I reassure the whole House that the Government agree with the intent of much of what has been debated today, but rather than developing a bespoke approach for psilocybin alone, we consider our approach to be more ambitious. We want to tackle this issue across all categories of section 1 drugs to reduce barriers to legitimate research, rather than focusing on individual drugs. Equally, we must keep a firm focus on the need to tackle drug misuse, which causes such harm across our society. Both are vitally important aims, and we will continue working to strike the right balance in the interests of the public.

Oral Answers to Questions

Debate between Robert Jenrick and Charlotte Nichols

Monday 14th November 2022 Commons Chamber

[Robert Jenrick]

I would be very happy to do so.

[Charlotte Nichols (Warrington North) (Lab)]

11. Whether she is taking steps with Cabinet colleagues to ensure that the potential health benefits of ingredients scheduled under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001 are kept under review.

Antisemitic Attacks

Debate between Robert Jenrick and Charlotte Nichols

Monday 17th May 2021 Commons Chamber

[Robert Jenrick]

Antisemitic crimes, like all those with regard to racism, are serious crimes, and we expect police forces investigating these issues to do so rigorously, robustly and swiftly, and for action to be taken against the individuals if they are found to require prosecution. My right hon. Friend the Home Secretary is working with the Metropolitan police, and has received assurances from them that they will be doing everything they can to bring these individuals to justice.

[Charlotte Nichols (Warrington North) (Lab) [V]]

Last night, Jewish communities across the country began our celebrations for the festival of Shavuot, and I wish all of those marking it a chag sameach. The scenes of antisemitic and misogynistic abuse yesterday have been incredibly disturbing and have caused significant alarm and distress, coming off the back of a rise in hate crime incidents both online and in physical attacks on and desecrations of our places of worship. I have been heartened by unequivocal condemnations from across society, including by the Muslim Council of Britain and the Palestinian ambassador in the UK, as they recognise that all forms of racism and oppression reinforce one another, that they cannot be fought in isolation from each other and that we all have more in common than that which divides us. What support, therefore, will the Secretary of State provide to interfaith initiatives such as the Warrington Ethnic Communities Association and the Muslim Jewish Forum of Greater Manchester to help us build solidarity and co-operation across our communities, where a minority of extremists seek to divide us?

Rough Sleeping

Debate between Robert Jenrick and Charlotte Nichols

Thursday 25th February 2021 Commons Chamber

[Charlotte Nichols (Warrington North) (Lab) [V]]

Official statistics estimate that 4,266 people were sleeping rough at the start of the pandemic, but the Government claim to have helped 33,000 rough sleepers into emergency accommodation. How does the Secretary of State square that circle, and will he commit to provide a richer and more frequent picture of homelessness and rough sleeping across the country to ensure that everyone’s basic human rights with regard to shelter can be met both as we come through the pandemic and in the longer term?

[Robert Jenrick]

The numbers that we publish today are a snapshot of a single night in November. Those are the most robust data sources that we have. They are the ones that we are able to measure ourselves on because they have been in place for more than 10 years now. I think that that is the right way forward.

The Everyone In programme did not help just those individuals who were actually sleeping rough on the streets. It also helped many people who were sofa surfing or in other forms of precarious accommodation who were at risk of ending up on the streets. So the success of the programme has been not just to get people off the streets but to help many thousands of other people who were otherwise in difficult circumstances to begin to move forward with their lives.